Published in Br J Haematol on April 01, 1999
Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options. Turk J Haematol (2014) 1.25
Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag (2009) 0.81
Acquired activated protein C resistance and thrombosis in multiple myeloma patients. Thromb J (2006) 0.81
Therapy strategies for multiple myeloma: current status. Wien Klin Wochenschr (2003) 0.81
Pretreatment Lymphopenia, Poor Performance Status, and Early Courses of Therapy Are Risk Factors for Severe Bacterial Infection in Patients with Multiple Myeloma during Treatment with Bortezomib-based Regimens. J Korean Med Sci (2016) 0.77
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma. Invest New Drugs (2009) 0.76
Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation. J Korean Med Sci (2013) 0.75
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. Br J Haematol (2009) 0.75
International uniform response criteria for multiple myeloma. Leukemia (2006) 17.78
Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med (2012) 15.43
Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med (1995) 9.72
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood (1994) 9.10
Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med (1995) 6.52
Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol (2007) 6.35
Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood (2000) 6.27
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med (1999) 5.82
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A (2008) 4.60
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia (2011) 4.47
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia (2008) 3.41
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest (1994) 3.30
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet (1998) 3.06
Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med (1995) 2.85
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia (2007) 2.76
Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol (2001) 2.71
Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet (2001) 2.70
Hyperhomocysteinaemia as a cardiovascular risk factor: an update. Neth J Med (2000) 2.47
Risk factors for fungal infection in patients with malignant hematologic disorders: implications for empirical therapy and prophylaxis. Clin Infect Dis (1994) 2.41
The application of hematopoietic growth factors in drug-induced agranulocytosis: a review of 70 cases. Leukemia (1994) 2.26
Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol (1989) 2.12
Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost (2003) 2.12
Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma. Lancet (2005) 2.03
The granularity of medical narratives and its effect on the speed and completeness of information retrieval. J Am Med Inform Assoc (1998) 2.03
[Simplified diagnosis of deep venous thrombosis by applying clinical score and D-dimer concentration]. Ned Tijdschr Geneeskd (2003) 2.02
Uveitis masquerade syndromes. Ophthalmology (2001) 2.02
Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet (2002) 2.01
Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis? Lancet (1995) 2.00
Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol (1999) 1.98
Skin biopsies in bone marrow transplantation. Lancet (1994) 1.95
[Thalidomide in the treatment of refractory multiple myeloma: a Dutch study of 72 patients: an antitumor effect in 45%]. Ned Tijdschr Geneeskd (2002) 1.93
Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet (1992) 1.92
Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res (2000) 1.91
Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity (2001) 1.90
Medical narratives in electronic medical records. Int J Med Inform (1997) 1.88
The glucocorticoid receptor cooperates with the erythropoietin receptor and c-Kit to enhance and sustain proliferation of erythroid progenitors in vitro. Blood (1999) 1.87
Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol (2001) 1.86
Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol (1998) 1.84
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82
Graft-versus-myeloma effect in two cases. Lancet (1996) 1.80
Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol (2002) 1.80
Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia (2006) 1.79
The release of endotoxin from antibiotic-treated Escherichia coli and the production of tumour necrosis factor by human monocytes. J Antimicrob Chemother (1993) 1.77
Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, The Netherlands. Ann Oncol (1996) 1.76
CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol (2003) 1.75
Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia (2012) 1.74
Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia (2004) 1.71
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol (2001) 1.70
Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation autoimmune diseases working party database. Mult Scler (2006) 1.70
Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia (2011) 1.70
Mutations in N-ras predominate in acute myeloid leukemia. Blood (1987) 1.68
Quantification of antigen-reactive cells among human T lymphocytes. Eur J Immunol (1978) 1.66
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia. Crit Rev Oncol Hematol (2004) 1.65
Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia (2000) 1.64
Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med (1987) 1.63
Interleukin-8 induces rapid mobilization of hematopoietic stem cells with radioprotective capacity and long-term myelolymphoid repopulating ability. Blood (1995) 1.62
Molecular epidemiology of apparent outbreak of invasive aspergillosis in a hematology ward. J Clin Microbiol (1996) 1.61
A simple and sensitive method for determining plasma cell isotype and monoclonality in bone marrow using flowcytometry. Br J Haematol (1995) 1.60
[Adjuvant systemic therapy for patients with resectable breast cancer: guideline from the Dutch National Breast Cancer Platform and the Dutch Society for Medical Oncology]. Ned Tijdschr Geneeskd (2000) 1.59
The effects of 5-aza-2'-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res (2004) 1.58
The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol (2009) 1.58
Bone marrow reconstitution after high-dose chemotherapy and autologous peripheral blood progenitor cell transplantation: effect of graft size. Ann Oncol (1994) 1.56
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis. Bone Marrow Transplant (1999) 1.55
Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol (2005) 1.55
Nocardiosis: a case series and a mini review of clinical and microbiological features. Neth J Med (2007) 1.54
Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9). Proc Natl Acad Sci U S A (1999) 1.49
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer. J Clin Oncol (1999) 1.48
[Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma]. Ned Tijdschr Geneeskd (2003) 1.47
Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood (2000) 1.47
Viridans streptococci isolated from the bloodstream. Relevance of species identification. Diagn Microbiol Infect Dis (1995) 1.46
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study. Leukemia (2008) 1.46
Plasma IL-8 and IL-6 levels can be used to define a group with low risk of septicaemia among cancer patients with fever and neutropenia. Br J Haematol (1999) 1.46
Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J Infect Dis (1985) 1.45
Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia (1999) 1.44
Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia (2012) 1.43
A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands. Br J Haematol (1997) 1.43
[Sigmoid carcinoma as a long-term complication following ureterosigmoidostomy]. Ned Tijdschr Geneeskd (2008) 1.43
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost (2007) 1.42
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant (2000) 1.42